Here's what traders need to know.
On top of all the other best-selling drugs in the firm's stable, Mounjaro has game-changer type potential.
I've noticed that biotech has been one area of strength lately.
Here's where aggressive traders could go long.
Amid positive news for Alzheimer's drug, donanemab, here's where the stock may be headed next.
Q1 revenue growth was driven by several drugs.
Here's how traders can play it.
Traders should operate from the long side.
Let's check the charts and indicators.
The trading days between the gaps look like an island surrounded by water.